MarketLens

Did Moderna's Q4 Earnings Beat Outweigh the Flu Vaccine Setback

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Moderna's Flu Vaccine Surge: A Chasm Between Market Hype and Wall Street's Skepticism

1 months ago

Did CF Industries' Q4 2025 Earnings Beat Signal a Turning Point

5 months ago

Has Target Finally Turned the Corner After Its Q4 Earnings Beat

5 months ago

Is New Gold (NGD) Poised for a Q4 Earnings Beat

6 months ago

Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future

Moderna's stock rose after the FDA approved its mRNA flu vaccine, mFlusiva, for adults 50 and older, offering a new growth avenue beyond COVID-19.

MRNA

Stock News•2 weeks ago

MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback

Moderna shares fell after Q2 revenue topped estimates, because its phase III norovirus vaccine study missed early success criteria. The setback clouds the company's pipeline outlook despite the earnin...

MRNA

Stock News•2 months ago

Does Moderna Need to Start Making Money?

Moderna is losing billions annually, but several promising new products are expected to launch within the next few years, potentially shifting its financial trajectory.

MRNA

Stock News•3 months ago

Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook

Moderna reported a Q1 2026 revenue beat driven by international vaccine sales, while reaffirming its full-year guidance of up to 10% growth. However, a $0.9B litigation charge resulted in a wider net ...

MRNA